|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||69.03 - 70.64|
|52 Week Range||52.51 - 71.47|
|PE Ratio (TTM)||26.53|
|Earnings Date||Feb 14, 2018 - Feb 19, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.85|
DaVita Inc. will pay $63.7 million to settle a whistle-blower lawsuit that alleged that the Denver-based company’s pharmaceutical division improperly billed the federal government for medications that were not used by patients and that it paid financial inducements to beneficiaries in violation of the federal anti-kickback laws. Two former DaVita employees also filed a whistle-blower lawsuit in U.S. District Court in northern Texas in 2016. This latest settlement follows DaVita agreeing to pay $389 million in 2014 to settle anti-kickback allegations surrounding joint ventures made with nephrologists and agreeing to pay $495 million in 2015 on a whistle-blower settlement regarding its billing over certain drugs that were only partially dispensed.
A Texas-based pharmacy chain that specializes in patients with kidney problems will pay nearly $64 million to settle allegations of improper billing and other disputed financial practices. Federal prosecutors ...
DENVER , Dec. 14, 2017 /PRNewswire/ -- The following media statement is attributable to DaVita (NYSE: DVA). We take full ownership and continue to embrace transparency and rigorous compliance. DaVita is ...
A pharmacy services unit of DaVita Inc will pay $63.7 million to resolve allegations that it improperly billed federal healthcare programs for medications and paid illegal financial inducements to patients, the U.S. Justice Department said. The settlement announced on Thursday will resolve an investigation by the Justice Department into DaVita Rx LLC, a national pharmacy that specializes in serving kidney disease patients.
A pharmacy services unit of DaVita Inc has agreed to pay $63.7 million to resolve allegations that it improperly billed federal healthcare programs for medications and paid illegal financial inducements ...
DaVita Physician Solutions helps solve for the physician experience through modern technology solutions DENVER , Dec. 14, 2017 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading independent medical group ...
DENVER , Dec. 13, 2017 /PRNewswire/ -- DaVita Kidney Care , a division of DaVita Inc. (NYSE: DVA), a leading provider in kidney care services, released its "Today's Kidney Diet: Home-Cooked Holidays" ...
Chairman and CEO of Davita Inc (NYSE:DVA) Kent J Thiry sold 81,800 shares of DVA on 12/08/2017 at an average price of $68.04 a share.
After a divestiture deal that could raise nearly $5 billion for kidney dialysis leader DaVita (DVA) is now 13% higher than the level where Barron's warned that insurers were attacking DaVita's profits ("Insurers Press Dialysis Claims," September 2, 2017). Bulls like John Ransom at Raymond James expect the company to repurchase stock and pay down debt with the proceeds from a December 6 deal to sell its medical practices to UnitedHealth Group (UNH). On December 7, the Raymond James analyst raised his rating on DaVita shares from Outperform to a Strong Buy, while upping his price target from $65 to $84.
The Dow endured a volatile week even as Republicans tasted success on the tax legislation front.
Stock Monitor: DaVita Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 08, 2017 / Active-Investors issued a free report on UnitedHealth Group Inc. (NYSE: UNH ), which is readily accessible upon ...
Rating Action: Moody's affirms DaVita's Ba2 CFR; outlook stable. Global Credit Research- 07 Dec 2017. New York, December 07, 2017-- Moody's Investors Service announced that it affirmed all ratings of DaVita, ...
UnitedHealth's (UNH) intention to buy DaVita Medical reflects its continuous effort to build up a vertically integrated business model
UnitedHealth Group Inc (NYSE:UNH), the dominant player in the U.S. health insurance market, has agreed to buy the medical clinic business of Davita Inc (NYSE:DVA) for $4.9 billion, accelerating consolidation in the healthcare space. This could mean good things for UNH stock. In describing the pending merger of CVS Health Corp (NYSE:CVS) and Aetna Inc (NYSE:AET), health insurers are looking to buy facilities and drug dispensing units so they can gain control over costs.
As CVS Health and Aetna seek to build an integrated health care company without doctors, rival UnitedHealth Group makes $4.9 billion deal to add more providers.
DaVita (DVA) soared to the top of the S&P 500 today after it sold its Medical Group for nearly $5 billion to UnitedHealth Group (UNH). DaVita gained 14% to $69.20 today, while the S&P 500 finished little changed at 2629.27. UnitedHealth dipped 0.1% to $219.94.
Stocks that moved substantially or traded heavily Wednesday: DaVita Inc., up $8.27 to $69.20 The dialysis services company agreed to sell a physician practice business to health insurer UnitedHealth for ...
Health insurers are trying to cut medical costs by playing a more direct role in medical services, arguing they can save money by shifting patients to cheaper, more accessible locations for routine or non life-threatening emergency medical services. On Sunday, No. 3 health insurer Aetna Inc agreed to be bought by CVS Health as part of a drive to expand medical services at CVS pharmacies to include more preventative screenings such as for vision and hearing.